At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 191 enrolled
Drug / intervention
Ruxolitinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Open-Label Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Subjects With Myelofibrosis (REFINE)
In Brief
A Phase 2 clinical trial evaluating Ruxolitinib and Navitoclax for Myelofibrosis (MF). Completed, enrolled 191 participants across 91 sites in 14 countries.
Detailed Summary
This is a Phase 2 open-label, multicenter study evaluating tolerability and efficacy of navitoclax alone or when added to ruxolitinib in participants with myelofibrosis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMyelofibrosis (MF)
CountriesAustralia, Canada, Croatia, Greece, Hungary, Israel, Italy, Japan, Puerto Rico, South Korea, Spain, Taiwan, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedJul 2017
Enrollment StartOct 2017
Primary CompletionMar 2022
Study CompletionJan 2025
TodayJul 2026
First PostedJul 19, 2017
Enrollment StartOct 31, 2017
Primary CompletionMar 28, 2022
Study CompletionJan 29, 2025
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 9.0 years ago
Interventions
Ruxolitinibdrug
Tablet; Oral
Navitoclaxdrug
Film-coated tablet; Oral